Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 396

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa

Open access
Molloy, Síle F., Kanyama, Cecilia, Heyderman, Robert S., Loyse, Angela, Kouanfack, Charles, Chanda, Duncan, Mfinanga, Sayoki, Temfack, Elvis, Lakhi, Shabir, Lesikari, Sokoine, Chan, Adrienne K., Stone, Neil, Kalata, Newton, Karunaharan, Natasha, Gaskell, Kate, Peirse, Mary, Ellis, Jayne, Chawinga, Chimwemwe, Lontsi, Sandrine, Ndong, Jean-Gilbert, Bright, Philip, Lupiya, Duncan, Chen, Tao, Bradley, John, Adams, Jack, van der Horst, Charles, van Oosterhout, Joep J., Sini, Victor, Mapoure, Yacouba N., Mwaba, Peter, Bicanic, Tihana, Lalloo, David G., Wang, Duolao, Hosseinipour, Mina C., Lortholary, Olivier, Jaffar, Shabbar, Harrison, Thomas S.·2018·New England Journal of Medicine

Abstract

BACKGROUND: Cryptococcal meningitis accounts for more than 100,000 human immunodeficiency virus (HIV)-related deaths per year. We tested two treatment strategies that could be more sustainable in Africa than the standard of 2 weeks of amphotericin B plus flucytosine and more effective than the widely used fluconazole monotherapy. METHODS: We randomly assigned HIV-infected adults with cryptococcal meningitis to receive an oral regimen (fluconazole [1200 mg per day] plus flucytosine [100 mg per kilogram of body weight per day] for 2 weeks), 1 week of amphotericin B (1 mg per kilogram per day), or 2 weeks of amphotericin B (1 mg per kilogram per day). Each patient assigned to receive amphotericin B was also randomly assigned to receive fluconazole or flucytosine as a partner drug. After induction treatment, all the patients received fluconazole consolidation therapy and were followed to 10 weeks. RESULTS: A total of 721 patients underwent randomization. Mortality in the oral-regimen, 1-week amphotericin B, and 2-week amphotericin B groups was 18.2% (41 of 225), 21.9% (49 of 224), and 21.4% (49 of 229), respectively, at 2 weeks and was 35.1% (79 of 225), 36.2% (81 of 224), and 39.7% (91 of 229), respectively, at 10 weeks. The upper limit of the one-sided 97.5% confidence interval for the difference in 2-week mortality was 4.2 percentage points for the oral-regimen group versus the 2-week amphotericin B groups and 8.1 percentage points for the 1-week amphotericin B groups versus the 2-week amphotericin B groups, both of which were below the predefined 10-percentage-point noninferiority margin. As a partner drug with amphotericin B, flucytosine was superior to fluconazole (71 deaths [31.1%] vs. 101 deaths [45.0%]; hazard ratio for death at 10 weeks, 0.62; 95% confidence interval [CI], 0.45 to 0.84; P=0.002). One week of amphotericin B plus flucytosine was associated with the lowest 10-week mortality (24.2%; 95% CI, 16.2 to 32.1). Side effects, such as severe anemia, were more frequent with 2 weeks than with 1 week of amphotericin B or with the oral regimen. CONCLUSIONS: One week of amphotericin B plus flucytosine and 2 weeks of fluconazole plus flucytosine were effective as induction therapy for cryptococcal meningitis in resource-limited settings. (ACTA Current Controlled Trials number, ISRCTN45035509 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1710922

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 396

Metadata

Authors
Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D., Mfinanga, S., Temfack, E., Lakhi, S., Lesikari, S., Chan, A. K., Stone, N., Kalata, N., Karunaharan, N., Gaskell, K., Peirse, M., Ellis, J., Chawinga, C., Lontsi, S., Ndong, J.-G., Bright, P., Lupiya, D., Chen, T., Bradley, J., Adams, J., van der Horst, C., van Oosterhout, J. J., Sini, V., Mapoure, Y. N., Mwaba, P., Bicanic, T., Lalloo, D. G., Wang, D., Hosseinipour, M. C., Lortholary, O., Jaffar, S., & Harrison, T. S.
Venue
New England Journal of Medicine
Published
2018-03-15
Volume
378
Issue
11
Pages
1004-1017
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2791888954
Cited by
396
References
26
FWCI
29.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. https://app.cochat.ai/papers/10.1056/nejmoa1710922
The paper
Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D., Mfinanga, S., Temfack, E., Lakhi, S., Lesikari, S., Chan, A. K., Stone, N., Kalata, N., Karunaharan, N., Gaskell, K., Peirse, M., Ellis, J., Chawinga, C., Lontsi, S., . . . Harrison, T. S. (2018). Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1710922

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.